Nabi Biopharmaceuticals (NASDAQ:NABI)
CAPS Rating:
The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.
RSS Headlines
Fool UK
Recs
Company's got alot of potential on the bench right now...anyone of which could be at least a double!